US equities
|
MU
$918.26
▲+0.45%
NVDA
$217.93
▼-1.52%
SNDK
$1,361.92
▼-2.95%
SPCX
$148.13
▼-2.65%
AMD
$561.05
▼-1.71%
INTC
$95.45
▼-2.72%
AAPL
$342.57
▼-0.11%
CRWV
$68.71
▲+4.45%
MU
$918.26
▲+0.45%
NVDA
$217.93
▼-1.52%
SNDK
$1,361.92
▼-2.95%
SPCX
$148.13
▼-2.65%
AMD
$561.05
▼-1.71%
INTC
$95.45
▼-2.72%
AAPL
$342.57
▼-0.11%
CRWV
$68.71
▲+4.45%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Corcept Therapeutics Incorporated - Common Stock
(NQ:
CORT
)
113.79
-2.44 (-2.10%)
Delayed Quote
Updated: 3:11 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Corcept Therapeutics Incorporated - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action
February 26, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
Corcept Therapeutics (NASDAQ: CORT) Investors Who Have Suffered Losses - Contact Kaplan Fox before April 21, 2026 Lead Plaintiff Deadline
February 26, 2026
NEW YORK, NY - February 26, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”)...
Via
TheNewswire.com
Topics
Lawsuit
Corcept Therapeutics (NASDAQ: CORT) Investors Who Have Suffered Losses - Contact Kaplan Fox before April 21, 2026 Lead Plaintiff Deadline
February 26, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Corcept Therapeutics (NASDAQ:CORT) Stock Falls After Q4 Earnings Miss Estimates
↗
February 24, 2026
Via
Chartmill
Topics
Earnings
CORCEPT THERAPEUTICS INCORPORATED (CORT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Corcept Therapeutics Incorporated Investors of Upcoming Deadline
February 26, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
February 25, 2026
From
SkyMedia, LLC
Via
GlobeNewswire
Law Offices of Howard G. Smith Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action
February 25, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
CORT Investors Deadline Alert: Kaplan Fox Announces Corcept Therapeutics, Inc. Securities Class Action Filed - Lead Plaintiff Deadline April 21, 2026
February 25, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
CORT Investors Deadline Alert: Kaplan Fox Announces Corcept Therapeutics, Inc. Securities Class Action Filed - Lead Plaintiff Deadline April 21, 2026
February 25, 2026
NEW YORK, NY - February 25, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”)...
Via
TheNewswire.com
Topics
Lawsuit
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – CORT
February 25, 2026
From
The DJS Law Group
Via
Business Wire
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst
↗
February 25, 2026
The company guided for $900 million to $1 billion in 2026 revenue.
Via
Stocktwits
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
February 24, 2026
From
The Schall Law Firm
Via
Business Wire
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
February 24, 2026
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
Corcept (NASDAQ:CORT) Misses Q4 CY2025 Sales Expectations
February 24, 2026
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 11.1% year on year to $202.1 million. Its GAAP profit of $0.20 per...
Via
StockStory
Topics
Artificial Intelligence
Supply Chain
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
February 24, 2026
From
Corcept Therapeutics Incorporated
Via
Business Wire
Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026
February 24, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026
February 24, 2026
NEW YORK, NY - February 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”)...
Via
TheNewswire.com
Topics
Lawsuit
INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
February 24, 2026
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Kaplan Fox Encourages Corcept Therapeutics, Inc. (CORT) Investors to Inquire About Ongoing Investigation
February 24, 2026
NEW YORK, NY - February 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:...
Via
TheNewswire.com
Kaplan Fox Encourages Corcept Therapeutics, Inc. (CORT) Investors to Inquire About Ongoing Investigation
February 24, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)
February 24, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
February 23, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
CORCEPT CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the Firm
February 23, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR ALERT: Securities Class Action Filed Against Corcept Therapeutics Incorporated – Investors Encouraged to Contact Kirby McInerney LLP
February 23, 2026
From
Kirby McInerney LLP
Via
Business Wire
Rosen Law Firm Urges Corcept Therapeutics Incorporated (NASDAQ: CORT) Stockholders to Contact the Firm for Information About Their Rights
February 23, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
CORCEPT THERAPEUTICS INCORPORATED (CORT) INVESTOR ALERT Investors With Large Losses in Corcept Therapeutics Incorporated Should Contact Bernstein Liebhard LLP To Discuss Their Rights
February 23, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
CORT Investors Notified of Investigation Into Corcept Therapeutics, Inc. by Kaplan Fox
February 23, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
CORT Investors Notified of Investigation Into Corcept Therapeutics, Inc. by Kaplan Fox
February 23, 2026
NEW YORK, NY - February 23, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:...
Via
TheNewswire.com
Corcept (CORT) Q4 Earnings: What To Expect
February 22, 2026
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday afternoon. Here’s what to expect.
Via
StockStory
Topics
Artificial Intelligence
World Trade
Kaplan Fox is Investigating Possible Securities Law Violations Against Corcept Therapeutics, Inc. (CORT)
February 21, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
3
4
5
6
7
8
9
...
22
23
Next >
